Sapho Bio Secures $5M, Advances Rapid Sterility Testing Through USP Validation

• Company secures $5M in funding to accelerate its rapid testing platform

• USP<1223> validation completed, reinforcing 20-hour testing method

• Faster test results replace the standard 14-day USP sterility test

SAN CARLOS, CA – April 20, 2026 – Sapho Bio, a biotechnology company developing a rapid microbiology release platform for precision medicine, announces over $5M in secured funding in an oversubscribed seed round, USP<1223> validation, and availability of rapid sterility test results. Together these milestones signal a pivotal inflection point for pharmaceutical qc, replacing a decades-old testing standard incompatible with short shelf life products.

Sapho Bio's growing pipeline spans rapid sterility testing, the company's first commercialized product and a sterility testing kit in development. The company leverages RNA-based detection to identify living bacteria and fungi, delivering results in approximately 20 hours, compared to the longer 14-day window demanded of traditional methods. This technology has already saved customers decades of testing time vs traditional sterility testing timelines. Sapho Bio's rapid sterility assay uses a proprietary RNA-based method, built on standard QPCR workflows, detecting viable contamination quickly and reliably without requiring specialized equipment. Critically this assay supports id in the event of positive test results.

"Today's announcement is a pivotal moment for Sapho Bio. The funding validates the market need and the validation proves the science," said Abraham Chaibi, co-founder and chief executive officer of Sapho Bio. "Our rapid sterility test delivers results within approximately 20 hours, reducing wait times for manufacturers and patients alike."

$5M in Funding to Accelerate a Platform for Rapid Microbiology Release

Sapho Bio has raised $5M to date to develop its platform. The company was founded in 2024 by Abraham Chaibi and John McSpedon. Advisors include Prof Jason Kahn, Richard Sportsman, and Ronenn Roubenoff, bringing deep expertise in drug discovery and assay design. Investors include Mochi Health, Rewon Child, Lawrence Diao and Amir Khan.

USP<1223> Validation Confirms Sapho Bio's Rapid Sterility Assay is Ready for QC Labs

Sapho Bio's USP<1223> validation demonstrates accuracy, precision, limit of detection, and more across hundreds of samples. Achieving this signals that the assay is ready for commercialization and it is now available through Sapho's lab services arm Analytic Services Express. "Our USP<1223> validation means that every test leaving our facility is statistically non-inferior to the traditional method and far faster" said John McSpedon, co-founder and CTO of Sapho Bio. One key benefit of the method is its robust support for id'ing positive samples.

For more information, visit: http://saphobio.com/.

About Sapho Bio

Sapho Bio is a biotechnology company developing a rapid microbiology release platform for precision medicines in the Bay Area. Sapho Bio's first product is an RNA-based rapid sterility assay detecting living bacteria and fungi in 20 hours, replacing the 14-day standard.

Media Contact

Sapho Bio PR: pr@saphobio.com